Transcranial Magnetic Stimulation

Frontal lobe syndrome can present with a range of perseverative, disinhibited, overactive behaviors that do not meet traditional dementia/neurocognitive disorder criteria. Learn more here.

Clinicians should consider rTMS as an intervention to alleviate OCD symptoms, especially in those who have failed other treatments or those with comorbid depression.

An expert shares more about the recent data on NeuroStar advanced TMS. Learn more here.

Negative symptoms pose significant challenges for individuals with schizophrenia and their caregivers.

According to new data, NeuroStar Advanced TMS helped nearly 60% of adolescents with major depressive disorder.

The FDA has granted clearance to the Horizon Inspire transcranial magnetic stimulation system to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression.

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.

A new study shows that rTMS has moderate therapeutic effects on OCD severity.

Adjunctive rTMS for antidepressant nonresponders? Researchers performed a randomized comparison with current antidepressant treatment approaches.

Baseline clinical factors and early improvement in overall and specific depressive symptoms predict response to rTMS in patients with depression.

Will this help my sleep and mood? Researchers investigated the effects of noninvasive neurostimulation on sleep quality and depressive symptoms in patients with major depressive disorder in a meta-analysis of randomized controlled trials.

Will this procedure help? Researchers investigated early symptom improvement and other clinical predictors of response to repetitive transcranial magnetic stimulation for depression.

What does the recent FDA clearance of this treatment for adolescents mean for the future of MDD treatment?

Here are some updates from the world of psychiatry throughout the month of March.

Our March CME reviews the principles and applications of invasive and noninvasive neuromodulation techniques for the treatment of mood disorders. Here are 5 key takeaways.

This treatment is now the first and only TMS treatment that is FDA-cleared for this patient population.

From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.

“Can I use this at home?” Researchers performed a randomized clinical trial of home-use transcranial direct current stimulation in patients with depression.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

The FDA granted clearance for a transcranial magnetic stimulation technology indicated for major depressive disorder and obsessive-compulsive disorder.

In this CME article, review the current treatment modalities for noninvasive brain stimulation in the treatment of substance use disorders, and to explore the potential for further expansion of indications.

From sleep disturbances in ADHD to psychotherapy for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

TMS for the treatment of neuropsychiatric symptoms in patients with long COVID appeared to improve their cognitive function and symptoms of depression.

What is new in research on TMS?

From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.

Adjunctive rTMS for treatment-resistant depression? Researchers performed a meta-analysis of 19 randomized sham-controlled trials.

What is new in research on transcranial magnetic stimulation?

Psychiatry: a field of medicine that is constantly evolving.

Investigators also concluded that rTMS may be effective as an adjunctive treatment for patients with MDD.

Transcranial magnetic stimulation treatment appeared to lessen some neuropsychiatric symptoms of long COVID in an open-label pilot study.